Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Alzamend Neuro Inc ALZN has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease.

• The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for a planned Phase 2 study in Alzheimer's patients. 
• Related Link: See Why Alzamend Neuro Stock Is Rallying On Thursday.
• The participants received a single dose of AL001 containing lithium equivalent to 150 mg lithium carbonate. 
• Dose-adjusted relative bioavailability analyses of the rate and extent of lithium absorption indicate that AL001 is bioequivalent to the marketed 300 mg lithium carbonate product. 
• The shapes of the lithium plasma concentration versus time curves are similar. 
• AL001 salicylate plasma concentrations were well-tolerated and consistently within safe limits.
• AL001 is a patented ionic cocrystal technology delivering lithium via a therapeutic crystal-engineered combination of lithium, L-proline, and salicylate.
• Price Action: ALZN shares are up 14.20% at $2.89 during the market session on the last check Friday.